Sociedad Americana de Hirudoterapia

Preparation and Application of Nanosensor in Safeguarding Heparin Supply Chain

Research article published in SLAS technology (2020)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportFarmacología salivalEnsayos clínicosSeguridad y control de infeccionesBi Y et al. · SLAS technology, 2020

Abstract

Heparin has been in clinical use as an anticoagulant for the last eight decades and used worldwide in more than 100 million medical procedures every year. This lifesaving drug is predominantly obtained from ~700 million pig intestines or bovine organs through millions of small and medium-sized slaughterhouses. However, the preparations from animal sources have raised many safety concerns, including the contamination of heparin with potential pathogens, proteins, and other impurities. In fact, contaminated heparin preparations caused 149 deaths in several countries, including the United States, Germany, and Japan in 2008, highlighting the need for implementing sensitive and simple analytical techniques to monitor and safeguard the heparin supply chain. The contaminant responsible for the adverse effects in 2008 was identified as oversulfated chondroitin sulfate (OSCS). We have developed a very sensitive, facile method of detecting OSCS in heparin lots using a nanosensor, a gold nanoparticle-heparin dye conjugate. The sensor is an excellent substrate for heparitinase enzyme, which cleaves the heparin polymer into smaller disaccharide fragments, and therefore facilitates recovery of fluorescence from the dye upon heparitinase treatment. However, the presence of OSCS results in diminished fluorescence recovery from the nanosensor upon heparitinase treatment, because OSCS inhibits the enzyme. The newly designed nanosensor can detect as low as 1 × 10-9% (w/w) OSCS, making it the most sensitive tool available to date for the detection of trace amounts of OSCS in pharmaceutical heparins. In this report, we describe a simple methodology for the preparation of nanosensor and its application in the detection of OSCS contaminants.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., Extramural
Indexed MeSH termsBiosensing TechniquesFluorescenceGoldHeparinMetal NanoparticlesNanotechnology

Resumen

Heparin has been in clinical use as an anticoagulant for the last eight decades and used worldwide in more than 100 million medical procedures every year.

Por qué esto importa para la hirudoterapia

Este estudio describe el desarrollo de un nanosensor de conjugado de nanopartículas de oro y colorante de heparina capaz de detectar contaminación por sulfato de condroitina sobresulfatado (OSCS) en heparina farmacéutica a concentraciones tan bajas como 1 × 10⁻⁹% (p/p), abordando las preocupaciones de seguridad destacadas por la crisis de la heparina contaminada de 2008 que causó 149 muertes. Si bien la heparina es un anticoagulante relevante para el panorama terapéutico más amplio en torno a la hirudoterapia, este estudio no involucra sanguijuelas, hirudina ni componentes derivados de sanguijuelas. Su relevancia para el dominio de ASH es solo tangencial, tocando de manera periférica el aseguramiento de la calidad de fármacos anticoagulantes en lugar de cualquier aspecto de la biología de la sanguijuela o la práctica de la hirudoterapia.

Citación

Preparation and Application of Nanosensor in Safeguarding Heparin Supply Chain

Bi Y et al. · SLAS technology, 2020

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.